Advertisement

Topics

Top five promising drugs Phase I (February 2014)

20:25 EDT 22nd September 2017 | BioPortfolio

THE FIVE MOST PROMISING DRUGS ENTERING PHASE I TRIALS - February 2014

Drug Disease Company
HTL-9936 Cognitive impairment Heptares Therapeutics
BIOD-531 Type 2 diabetes Biodel
SGN-LIV1A LIV-1-positive metastatic breast cancer Seattle Genetics
PulmoXen Cystic fibrosis Xenetic Biosciences / Pharmasynthez
ESN-364 Sex-hormone related disorders such
as endometriosis, polycystic ovarian syndrome and uterine fibroids
EuroScreen

 

 

 

 

 

 

 

Source: Thomson Reuters Cortellis Competitive Intelligence.

Quick Search
Advertisement
 

review and buy Top five promising drugs Phase I (February 2014) market research data and corporate reports here